Canada: Canadian Patent Term Extension – The Treaty Text Is Released

Last Updated: December 10 2014
Article by Noel Courage

A First Look at Canada-Europe Free Trade Agreement Text on Patent Term Restoration and Other Exclusivities

Canada and Europe announced in October 2013, an agreement in principle on a Comprehensive Economic and Trade Agreement (CETA). Its most significant aspect was the potential increase of some Canadian drug patent terms by up to two years. The treaty text was released by the Canadian government on September 26, 2014. This article focuses on pharmaceutical IP, which is primarily covered in Article 9 of Chapter 22 in the treaty text. 

Background on CETA

CETA was the product of several years of negotiations. It is a wide-ranging trade agreement covering diverse topics such as foreign ownership and investments, access to public procurement contracts, automobiles, food (e.g. beef and dairy products) and agriculture. Pharmaceuticals were also a prominent part of the discussion. The agreement was negotiated in secret. Europe was reportedly pressuring Canada to strengthen exclusivities for brand name drugs. The main pharmaceutical intellectual property issues on the table were: i) providing patent term extension, ii) longer period of data exclusivity protection for brand name drugs to keep generics off the market, and iii) improving the right of pharmaceutical companies to appeal a loss in certain specialized pharmaceutical patent litigation cases called "NOC Proceedings".

Patent Term Restoration

Patents give companies the exclusive right to use an invention for a time period, typically up to twenty years from the patent filing date. Patent term restoration of two to five years must be available under the treaty terms1. The Canadian government has said that extensions will be capped at a maximum of two years. 

According to par. 9.2(2) of the treaty text, the restoration is available upon request of the brand name company, provided the drug is being approved by Health Canada for the first time. There will be no stacking of multiple patent term extensions – one restoration of one patent term per drug, available to the first company to get the drug approved. Where there are multiple patents, the brand name company may have some flexibility to select the benefiting patent2. An eligible patent will have to cover one or more of a product per se (i.e., active ingredient or combination), a process to obtain a product or the use of a product (e.g., medical treatment).

The additional protection of patent term restoration will be limited to the specific compound and its approved uses, not the entirety of the patent (for example, if the patent covers non-commercialized drugs, the non-commercialized drugs will not be protected further)3. This is a similar concept as U.S. patent term extension for FDA regulatory delays. This extension will be available only to drugs entering the market after the new rules come into effect. The CETA text provides an exception under the patent term extension for generic drugs to be exported, which was a carve-out promised by Canada to benefit its generic drug industry4.

Improved Brand Name Rights of Appeal of Court Decisions

The treaty also provides in very general terms for improved brand name company rights to appeal NOC Proceeding court decisions5. An NOC Proceeding is a court hearing between a brand name company and generic company that reviews patent issues to determine whether a generic company can get its marketing authorization. There is no further information currently available on the nature of these significant litigation changes that have been sought by Canada's brand name pharmaceutical companies for many years.

Data Protection

Canadian data protection for brand name drug companies was discussed in the CETA negotiations, but not changed. It will remain at eight years, which was the Canadian government's preference. The treaty shows that these standards will become a minimum treaty obligation through CETA, which would mean that it is more entrenched, and the time period couldn't be readily reduced in future without Canada being in breach of the trade agreement6. During the data protection period, a generic drug company cannot get its marketing authorization by relying on the brand name company's clinical trial data. The rationale for data protection is that brand name companies spend years, and millions of dollars, generating their clinical trial data – it should then not be made immediately available for generic competitors to use for their own purposes as an inexpensive shortcut to get their approval. This data protection period allows the brand name companies an opportunity to recoup their large R&D investment and make a profit. 

The treaty also provides for at least ten years of data protection for plant protection products, running from the date of first regulatory authorization7. These "products" are not defined, but this text will be of significant interest to the agricultural industry. 

Government-Company Trade Disputes Over Expropriation

In a development made public for the first time, there is a limited carve-out of certain IP issues from expropriation provisions8. The treaty states that limitation of IP rights are not expropriation, to the extent that these measures are consistent with CETA and the WIPO Trade Agreement known as "TRIPS"9. As well, any determination of inconsistency does not establish expropriation. This does not appear to go far in protecting the countries from pharmaceutical company trade disputes after patents are invalidated on the basis of Canadian court decisions. The issue is that the Canadian government may want to prevent a pharmaceutical company from taking the position that the court's invalidation of the patent applied judge-made law that is inconsistent with international trade obligations, or effectively an expropriation of IP rights. Canada is currently engaged in a trade arbitration with Eli Lilly & Company under the North American Free Trade Agreement following Canadian court invalidation of a couple of valuable Eli Lilly drug patents. 

Next Steps 

The next Canadian federal election is expected in 2015, so the government may aim to have the treaty signed by then. CETA would be in jeopardy if it remained an unratified treaty at election time and there was a change in power.

The federal governments must then pass new laws to implement the patent provisions of CETA. It is unclear the extent to which the government would consult with Canadian stakeholders prior to bringing in new laws. Implementation of this complex trade agreement would be staged so that different portions of laws come into effect at different times. Stay tuned for more information about the timing of pharmaceutical patent changes coming into force.

Footnotes

1. The calculation is as follows in par 9.4(a): "...protection shall be for a period equal to the period which elapsed between the date on which the application for a patent was filed and the date of the first authorisation to place the product on the market of that Party as a pharmaceutical product reduced by a period of five years."

2. 9.2(4).

Par. 9.2(5).

4. Par. 9.2(5).

5. Article 9 bis.

6. Article 10. The treaty states that this minimum eight year period will consist of at least six years where a generic company cannot file an abbreviated new drug submission, and at least two

7. Article 11.

8. Chapter 10. Investment, Article X.11: Expropriation.

9. Article X.11(6). TRIPS is the "Agreement on Trade-Related Aspects of Intellectual Property Rights".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Bereskin & Parr LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Bereskin & Parr LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions